Selumetinib received FDA approval for adults with NF1 and symptomatic, inoperable plexiform neurofibromas, based on the phase 3 KOMET trial results. The KOMET trial showed a 20% objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results